China NMPA Drug Inspection - Nanjing Tongrentang Huangshan Refined Pharmaceutical Co., Ltd. - Lotus seed heart
China NMPA drug inspection for Nanjing Tongrentang Huangshan Refined Pharmaceutical Co., Ltd. published April 28, 2020. Drug: Lotus seed heart. On April 28, 2020, the Shanghai Municipal Drug Administration published the results of its first-quarter drug quality sa
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Nanjing Tongrentang Huangshan Refined Pharmaceutical Co., Ltd. published April 28, 2020. Drug: Lotus seed heart. On April 28, 2020, the Shanghai Municipal Drug Administration published the results of its first-quarter drug quality sa
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox